Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
GHRP-2 activates the GHS-R1a (ghrelin) at the pituitary, releasing growth hormone. work indicates a partial dependence on -receptor co-signalling, with characteristic synergy when GHRP-2 and GHRH are co-administered in humans.
02
Research applications
- Growth hormone secretion pharmacology
- GH-deficiency diagnostic research
- Mechanism research on GHRP / -R interaction
- Anti-doping detection methodology
Evidence at a glance
What's behind this profile
3 citations · 1996–2010
- Human
- 2
- In vitro
- 1
Studies in human volunteers or patients (incl. early-phase trials).
Cell, tissue, or biochemical assays outside a living organism.
Publication years
- 96
- 97
- 98
- 99
- 00
- 01
- 02
- 03
- 04
- 05
- 06
- 07
- 08
- 09
- 10
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans
1996
Bowers CY et al. · Journal of Pediatric Endocrinology & Metabolism
- Model
- Human pharmacology — chronic administration study
- Sample
- Not reported in abstract
Reported that chronic GHRP-2 or administration converted additive GH responses to synergistic responses across dose levels and frequencies.
Is GHRH receptor essential to GHRP-2-induced GH secretion in primary cultured rat pituitary cells?
2002
Roh SG et al. · Endocrinology
- Model
- In vitro — primary cultured rat pituitary cells with antisense knockdown
- Sample
- Not reported in abstract
Using antisense oligonucleotides, the was found essential for GHRH-induced GH secretion but only partially required for GHRP-2-stimulated secretion.
Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography / tandem mass spectrometry
2010
Okano M et al. · Rapid Communications in Mass Spectrometry
- Model
- Analytical / detection method development with human volunteer administration
- Sample
- n=10
Developed and validated an LC-MS/MS method that detected unchanged GHRP-2 and a primary metabolite in all ten volunteer urine samples after intravenous administration.
Evidence caveats
- GHRP-2 (pralmorelin) is a diagnostic agent in Japan and is not FDA-approved in the United States.
- Primary human evidence is from small pharmacology studies; long-term safety and efficacy outside diagnostic contexts have not been established.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain batch traceability for comparison work.
- Avoid repeated cycles where not protocol-supported.
- Research-only inventory must be clearly separated from approved clinical material.